<SUBMISSION>
<ACCESSION-NUMBER>0001144204-05-030705
<TYPE>6-K
<PUBLIC-DOCUMENT-COUNT>4
<PERIOD>20051004
<FILING-DATE>20051004
<DATE-OF-FILING-DATE-CHANGE>20051004
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>3826
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>051119337
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v026688-6k.htm
<TEXT>
<html>
  <head>
    <title>
      Unassociated Document
</title><!-- Licensed to: vf-->
<!-- Document Created using EDGARIZER HTML 3.0.0.26435 -->
<!-- Copyright 2005 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><a name="return"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
        AND EXCHANGE COMMISSION</strong></font></a></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
        D.C. 20549</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>FORM
        6-K</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT
        OF
        FOREIGN ISSUER</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to Rule 13a-16 or 15d-16 of</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
        Securities Exchange Act of 1934</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>For
        the month of October 2005</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commission
        File Number 000-5112</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>pSivida
        Limited</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
        of registrant&#8217;s name into English) </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level
        12
        BGC Centre</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28
        The
        Esplanade</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth
        WA
        6000</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
        of principal executive offices)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate
        by check mark whether the registrant files or will file annual reports under
        cover Form&#160;20-F or Form&#160;40-F). </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
        20-F
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form
        40-F </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark if the registrant is submitting the Form 6-K in paper as permitted
        by Regulation S-T Rule 101(b)(1):</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark if the registrant is submitting the Form 6-K in paper as permitted
        by Regulation S-T Rule 101(b)(7):</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark whether the registrant by furnishing the information contained
        in
        this Form is also thereby furnishing the information to the Commission pursuant
        to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
        "Yes"
        is marked, indicate below the file number assigned to the registrant in
        connection with Rule&#160;12g3-2(b): 82- ___. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURE
        </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to the requirements of the Securities Exchange Act of 1934, the registrant,
        pSivida Limited, has duly caused this report to be signed on its behalf by
        the
        undersigned, thereunto duly authorized. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
        <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

            <tr valign="top" bgcolor="#ffffff">
              <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                Limited</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:&#160;October
                4, 2005</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:&#160;&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/&#160;Aaron
                Finlay</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td colspan="2"><font style="FONT-FAMILY: Times New Roman" size="1">&#160;</font></td>
              <td align="left">
                <hr style="COLOR: #000000" align="left" noshade size="2" width="80%"><font size="2">Aaron
                Finlay</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Chief
                Financial Officer and Company
                Secretary</em></font></td>
            </tr>

        </table>
      </div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="HDR">&#160;</div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="left">
            </div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
            </div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right">
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>EXHIBIT
        INDEX</u></em></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div align="left">
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td align="left" valign="top" width="15%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EXHIBIT
                  99.1:</strong></font></div>
              </td>
              <td align="left" valign="top" width="82%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CDS
                  launches Phase III trial for Retinal condition and Additional information
                  on CDS revenues.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
    </div>
    <div>&#160;</div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v026688-ex99_1.htm
<TEXT>
<html>
  <head>
    <title>
      Unassociated Document
</title><!-- Licensed to: vf-->
<!-- Document Created using EDGARIZER HTML 3.0.0.26435 -->
<!-- Copyright 2005 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body>
    <div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">EXHIBIT
        99.1</div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><img src="logo.jpg" alt=""></div>
      <div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ASX/MEDIA
          RELEASE</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 161.1pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 0.9pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>4
          October 2005</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

              <tr valign="top" style="LINE-HEIGHT: 1.25">
                <td align="right" style="WIDTH: 63pt"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Wingdings"><strong>&#167;&#160;&#160;</strong></font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>CDS
                    launches Phase III trial for Retinal
                    condition</strong></font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
        <div>
          <table cellpadding="0" cellspacing="0" id="list" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

              <tr valign="top" style="LINE-HEIGHT: 1.25">
                <td align="right" style="WIDTH: 63pt"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Wingdings"><strong>&#167;&#160;&#160;</strong></font></td>
                <td>
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>Additional
                    information on CDS
                    revenues</strong></font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
          <div>
            <hr style="COLOR: #000000" align="left" noshade size="1" width="100%">
          </div><br><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Medidur</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup><strong>TM</strong></sup></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Global
          bio-nanotech company pSivida Limited </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(ASX:PSD,
          NASDAQ:PSDV, Xetra:PSI)</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          is
          pleased to announce that Control Delivery Systems in collaboration with
          Alimera
          Sciences has initiated a Phase III clinical trial </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">to
          study
          diabetic macular edema (DME) patients treated using Medidur&#8482; to deliver
          fluocinolone acetonide. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
          announced earlier today that it has entered into a definitive merger agreement
          to acquire </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Control
          Delivery Systems.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
          copy of
          the Alimera Sciences media release is attached.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>CDS
          Revenues</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Control
          Delivery Systems had unaudited revenues of US$8 million for the year ended
          30</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>th</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          June
          2005 which does not include Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          royalties as marketing of that product has only recently commenced by Bausch
          &amp; Lomb.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Retisert</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup><strong>TM</strong></sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
          for Uveitis</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bausch
          &amp; Lomb&#8217;s </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM
          </sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">is
          the
          world&#8217;s first intravitreal drug implant for the treatment of this condition that
          affects an estimated 175,000 people in the United States and an estimated
          800,000 people worldwide. The product received FDA fast track status, designed
          to allow for priority review of novel therapies for serious diseases for
          which
          there is an unmet medical need. It also received FDA orphan drug designation
          for
          this indication. Control Delivery Systems anticipates receiving royalties
          from
          Bausch &amp; Lomb from this product this year.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-ENDS-</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Released
          by:</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div>
          <table cellpadding="0" cellspacing="0" width="100%">

              <tr>
                <td align="left" valign="top" width="26%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSivida
                    Limited</strong></font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Brian
                    Leedman</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor
                    Relations</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                    Limited</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                    + 61 8 9226 5099</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">brianl@psivida.com</font></div>
                </td>
                <td align="left" valign="top" width="26%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>US
                    Public Relations</strong></font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beverley
                    Jedynak</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">President</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Martin
                    E. Janis &amp; Company, Inc</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                    +1 (312) 9 1100 ext. 12</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">bjedynak@janispr.com</font></div>
                </td>
                <td align="left" valign="top" width="26%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UK
                    &amp; Europe Public</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Relations</strong></font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mark
                    Swallow, PhD / Helena Podd</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Citigate
                    Dewe Rogerson</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                    +44 (0)20 7638 9571</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">mark.swallow@citigatedr.co.uk</font></div>
                </td>
              </tr>

          </table>
        </div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="HDR">&#160;</div>
          <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div id="FTR">
              <div id="GLFTR" style="WIDTH: 100%" align="left">
              </div>
            </div>
            <div id="PN" style="PAGE-BREAK-AFTER: always">
              <div style="WIDTH: 100%; TEXT-ALIGN: center">
              </div>
              <div style="WIDTH: 100%; TEXT-ALIGN: center">
                <hr style="COLOR: black" noshade size="2">
              </div>
            </div>
            <div id="HDR">
              <div id="GLHDR" style="WIDTH: 100%" align="right">
              </div>
            </div>
          </div>
          <div>&#160;</div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>NOTES
          TO EDITORS:</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSivida
          Limited</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
          is a global bio-nanotech company committed to the biomedical sector and
          the
          development of products in healthcare. The company&#8217;s focus is the development
          and commercialisation of a modified form of silicon (porosified or
          nano-structured silicon) known as BioSilicon&#8482;. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
          owns the intellectual property pertaining to BioSilicon&#8482; for use in or on humans
          and animals. The IP portfolio consists of 29 patent families, 34 granted
          patents
          and over 80 patent applications. The core patent, which recognises BioSilicon&#8482;
          as a biomaterial was granted in the UK in 2000 and in the US in 2001.
</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
          is listed on NASDAQ (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSDV</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">),
          the
          Australian Stock Exchange (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)
          and in
          Germany on the Frankfurt Stock Exchange on the XETRA system (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>German</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Symbol:
          PSI. Securities Code (WKN) 358705</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).
          pSivida&#8217;s shares also trade in the United Kingdom on the OFEX International
          Market Service (IMS) under the ticker symbol </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
          pSivida
          is a founding member of the NASDAQ Health Care Index and the Merrill Lynch
          Nanotechnology Index.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          Company&#8217;s strategic partner and largest shareholder is the QinetiQ group, the
          largest science and technology company in Europe. QinetiQ is the former
          UK
          government Defence Evaluation Research Agency and was instrumental in
          discovering BioSilicon&#8482;. pSivida enjoys a strong relationship with QinetiQ
          having access to its cutting edge research and development facilities.
          For more
          information on QinetiQ visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.qinetiq.com</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
          more
          information visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.psivida.com</u></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
          announcement does not constitute an offer of any securities for sale or
          the
          solicitation of an offer to buy any securities. Any securities offered
          may not
          be or have not been registered under the US Securities Act of 1933, as
          amended,
          and may not be offered or sold in the United States absent registration
          or an
          applicable exemption from registration requirements."</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
          document contains forward-looking statements that involve risks and
          uncertainties. Although we believe that the expectations reflected in such
          forward-looking statements are reasonable at this time, we can give no
          assurance
          that such expectations will prove to be correct. Given these uncertainties,
          readers are cautioned not to place undue reliance on such forward-looking
          statements. Actual results could differ materially from those anticipated
          in
          these forward-looking statements due to many important factors including:
          our
          failure to develop applications for BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Arial, sans-serif"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          due to
          regulatory, scientific or other issues, our inability to negotiate and
          consummate the proposed acquisition, our inability to successfully integrate
          the
          CDS&#8217;s operations and employees; the failure of the CDS&#8217;s products</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          to
          achieve expected revenues and the combined entity&#8217;s inability to develop
          existing or proposed products. Other reasons are contained in cautionary
          statements in the Registration Statement on Form 20-F filed with the U.S.
          Securities and Exchange Commission, including, without limitation, under
          Item
          3.D, "Risk Factors" therein. We do not undertake to update any oral or
          written
          forward-looking statements that may be made by or on behalf of
          pSivida.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="left">
            </div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
            </div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right">
            </div>
          </div>
        </div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>Alimera
          Sciences, in Collaboration with Control Delivery Systems, Initiates Phase
          III
          Trial for Retinal Condition</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><img src="logo_pr.jpg" alt=""></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>New
          technology may improve vision for patients with diabetic macular
          edema</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ATLANTA,
          GA (October 3, 2005) - Alimera Sciences Inc., a dynamic ophthalmic
          pharmaceutical company, in collaboration with Control Delivery Systems
          Inc.
          (CDS), a leader in innovative drug delivery systems for the eye, recently
          initiated a Phase III clinical trial to study diabetic macular edema (DME)
          patients treated using Medidur&#8482; with fluocinolone acetonide, the companies&#8217;
          pharmacologic treatment for DME. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          masked, randomized, multi-center study will follow 900 patients in the
          U.S. and
          Europe for 36 months. Patients will receive the Medidur implant, which
          is small
          enough to be injected through a needle during an in-office procedure and
          is
          expected to provide sustained delivery of fluocinolone acetonide to the
          back of
          the eye for up to three years. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">"Advanced
          therapies require innovative methods of delivery, and Medidur fits that
          model.
          The Alimera Sciences team is delighted to reach this critical product
          development milestone with CDS at such a stage of our company&#8217;s progression,"
          said Dan Myers, CEO of Alimera Sciences. "We anticipate that Medidur technology
          will allow eye care professionals to provide their DME patients with an
          effective and long-lasting therapeutic treatment." </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
          February 2005, Alimera Sciences and CDS announced a worldwide agreement
          to
          co-develop and market Medidur using fluocinolone acetonide to treat DME.
          Alimera
          Sciences also has the option to develop three additional products using
          Medidur.
</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">"We
          are
          very pleased to have entered Phase III with this next generation of intraocular
          drug delivery systems", said Paul Ashton, CEO of CDS. "The first two products
          for CDS, Vitrasert&#174; and Retisert&#8482;, are the only two sustained release systems
          approved by the FDA for the back of the eye." </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">DME
          is a
          common complication of diabetic retinopathy and is caused by fluid build-up
          in
          the central vision portion of the retina. In 2002, the Centers for Disease
          Control and Prevention estimated the prevalence of diabetes in the United
          States
          to be 18.2 million persons. Research indicates that up to 10 percent of
          all
          diabetes patients develop DME during their lifetimes. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
          only
          approved method for treating DME involves laser photocoagulation therapy,
          which
          can leave irreversible blind spots. While there are no drugs approved by
          the FDA
          for DME, there is clinical evidence that corticosteroids reduce edema associated
          with DME. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">About
          Alimera Sciences Inc.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Alimera
          Sciences Inc. specializes in the development and commercialization of
          over-the-counter and prescription ophthalmology pharmaceuticals. Founded
          by an
          executive team with extensive development and revenue growth expertise,
          Alimera
          Sciences&#8217; products address both the anterior (front) and posterior (back)
          segments of the eye. In August 2004, Alimera Sciences unveiled</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Soothe&#174;,
          the market&#8217;s first multi-dose, emollient-based artificial tear product.
</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.alimerasciences.com</u></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">About
          Control Delivery Systems, Inc.</font></div>
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Control
          Delivery Systems, Inc. develops innovative, sustained-release, drug delivery
          products </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">to
          treat
          severe and chronic diseases that currently have limited or no effective
          treatment </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">options.
          CDS has a strong history of developing drug delivery devices for the back
          of the
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">eye,
          including one product for cytomegalovirus retinitis, a blinding eye disease
          primarily </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">afflicting
          late-stage AIDS patients, and Retisert&#8482;, which was recently approved by
          the</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FDA
          to
          treat non-infectious uveitis affecting the posterior segment of the eye.
          CDS, a
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">privately
          held company, is headquartered in Watertown, MA.</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Vitrasert&#174;
          and Retisert&#8482; are trademarks of Bausch &amp; Lomb Incorporated. </font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="left">
            </div>
          </div>
          <div id="PN">
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
            </div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right">
            </div>
          </div>
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X0HV17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````4````<@$R``(````4````AH=I``0````!````G````,@```!(````
M`0```$@````!061O8F4@4&AO=&]S:&]P(#<N,``R,#`U.C$P.C`T(#`T.C$T
M.C`T``````.@`0`#`````?__``"@`@`$`````0```-B@`P`$`````0```#T`
M````````!@$#``,````!``8```$:``4````!```!%@$;``4````!```!'@$H
M``,````!``(```(!``0````!```!)@("``0````!```)"`````````!(````
M`0```$@````!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``O_N
M``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43
M$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-
M$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#/_``!$(`"0`@`,!(@`"$0$#$0'_W0`$``C_Q`$_```!
M!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$`
M`@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@`,`P$``A$#$0`_`/54R=9/4@,;(9DT-V/!!?M$;MSMKVOCZ6Y0<SG]C'[A
MCQ1!]>NL8_O)B+-.LJ'4>L4X5C,9E5N7FVMW58E#=SRV0SU++';*,:G<?Y[)
MMJK_`+:R^HY>!D7W?8G%[Z+33E6-W;#:&[G4M?\`S=EE'^']/^9?^BL_2*\_
M]5Z0U]$LLO;7N=))W/V[G#=^<JYY\QS9\<L8`Y>/N2D)WQ1,>*'!'@^;_"3P
MV`0=S6WVH7XO5,BI^5UG.^P8U;38_%PW[&L8V7N.5U%X;D6;6?2=C_8:_P#C
M/IHOU8;FCI0LRWVO%UMEN*W(UN9C/<78E>0]VZQUOH[7N]7]+7O]*S^;4Z^E
M8F1CU-M9-0?OLK@`6.K=^A]?_2LK=^DV/_PBL]3ZCC],P+L_)W&G';N?L&YT
M2&^UOS5S%,SQQD1PF0XN&^*K\?2QF(B2?W>K:27-._Q@_5YK\>3?Z61$Y'I$
M55N(!=5;:?\`"U;V^OZ/K>C_`(1:/6,FZNRFAEAI99J^T>$@<_R)W.3.9SQP
M8CED"0*%#J9'ABF!C,U$@TZB2SL:C/HR6[;CD8KQ+G/=)_L?2_\`(*=GV;]K
M5;G6"_9[6C^;B'_2_E?23!S),`98SC)R1Q<.0\/S_I8Y^J.1?P^-Z6WDEF=.
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M-F><)N)TXN9DYEK,=U]8EU%5A_3YD?\`!5-?Z+O^Y'I(S?V1T#IE=9?5@X&*
MT,87N#6C^T_Z=ECO^N6V)F3'#)`PF.*,A1".(WH:KJYG4:<FBFFJX5!K2\L-
M0(DGW6.>V&MW.<=RMU8N;E48S;'5-QV-:YK1N+CI['/^C[O[2HYN7E=7%;\/
M'NHQ&R6Y-E1]6P'_`+BXE@_1-T_I&>QG_!8F4MCIC6,Q6UM98Q[6M%AM#MQ,
M?Z2W^<67#DXGG<T<DY&,XPX8\9X\G`(_SDO^XXN-DX_2*&W7_O6U76VMC6-X
M:("Q?KK_`.);J/\`Q8_ZIBW%C_6^B_(^K6?3CUONM?6`RNMI<YQW-^BQON<M
M>(`H#0#1BR:PE_=+Q772/_&SZ1Q/K"/\W*E=YD787HX^+F-)-C6D.(@-,;=W
MJ:;5SO0/J1TC*Z7T_+ZEBVUY;&[K\=Y>QKGAWTLC&=^?[&;_`/3?X;U%UN3B
M493`RYNX#5IX(^#@HN:C.>*4<?`9'IE'%CD/THR6<O$@\4M+C$:?U0Y=8LZ=
MU&O&JL-E-I$UGMNT_P`[\Y&N_P"7J/\`BS^2U6<7IF)BO]2MI+^SG&2)_=17
M8E+LEN40?58-K3)B/=^;_;5''R688XQ/#$#F,>>.+BE..'%CEQ2A&<FP9"_I
M5O`_6RX]!^LN=F-!V=7Z=96UPTVVPVG=_P!;]&E__75<R.G_`+._Q8.H(BQ]
M-=UGCNMMKNVG^HU_IKI>M_5SI7712.HUN?\`9RXU[7N9]/;O:=A&YKMC59ZE
MT[%ZG@VX&4TG'N`#VM):8:0]L.9[OI-6I>S5.$WDU'J!$/\`#^9X+ZQ3_P"-
MKTB/&G_SW<KOUL=6>J?5+TR"SU6%NV(VFS"VQ'YJZBSZO]+MZ,WHEE9?A,:U
MC&EQW#8=U;VVSOWL=^<J&/\`47ZO8YQGLJL-N)8VZNYUCB\N:6NK:]T_S5>S
MV4?S/^>E:#AEK5:B'_C;2ZGU!]WUI/3>A8.*>L55;LGJF4T'TF%K?;7LBZUV
MRZK\_P#POI_Z7TZGU!;8WK_U@;;:,BP6`67@!HL<+<G?:VMI<UGJ.]VQ;O5/
MJ=T/JF>.H9-=@O(`L-5CJQ8`-GZ7TRUW\W^C]FS]&K'2?JYTGHU^1?T^HTG)
M@/9N)8`TN<QM=9]M;6[_`,U*]$^W,Y!(U0D3]"/W7__1[#ZT_8_MF)'[2_:.
MRST_V5_.>C+/5^T^I^A]#U?2V>I_A/YM"Z-_S2^WU>IZO[:@>G^U_5^U=X^S
M?;_9_P"P"^?TD>C#_E#\OU_E\S]5)+Y5209GZJ27RJDDI^JDE\JI)*?JI)?*
MJ22GZJ27RJDDI^JDE\JI)*?JI)?*J22G_]G_[0[P4&AO=&]S:&]P(#,N,``X
M0DE-!"4``````!``````````````````````.$))30/M```````0`$@````!
M``$`2`````$``3A"24T$)@``````#@`````````````_@```.$))300-````
M```$````>#A"24T$&0``````!````!XX0DE-`_,```````D```````````$`
M.$))300*```````!```X0DE-)Q````````H``0`````````!.$))30/U````
M``!(`"]F9@`!`&QF9@`&```````!`"]F9@`!`*&9F@`&```````!`#(````!
M`%H````&```````!`#4````!`"T````&```````!.$))30/X``````!P``#_
M____________________________`^@`````________________________
M_____P/H`````/____________________________\#Z`````#_________
M____________________`^@``#A"24T$`````````@`!.$))300"```````$
M`````#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````-)````!@``````````````/0```-@````*`%4`;@!T
M`&D`=`!L`&4`9``M`#$````!``````````````````````````$`````````
M`````-@````]``````````````````````$`````````````````````````
M$`````$```````!N=6QL`````@````9B;W5N9'-/8FIC`````0```````%)C
M=#$````$`````%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O
M;6QO;F<````]`````%)G:'1L;VYG````V`````9S;&EC97-6;$QS`````4]B
M:F,````!```````%<VQI8V4````2````!W-L:6-E241L;VYG``````````=G
M<F]U<$E$;&]N9P`````````&;W)I9VEN96YU;0````Q%4VQI8V5/<FEG:6X`
M```-875T;T=E;F5R871E9`````!4>7!E96YU;0````I%4VQI8V54>7!E````
M`$EM9R`````&8F]U;F1S3V)J8P````$```````!28W0Q````!`````!4;W`@
M;&]N9P``````````3&5F=&QO;F<``````````$)T;VUL;VYG````/0````!2
M9VAT;&]N9P```-@````#=7)L5$585`````$```````!N=6QL5$585`````$`
M``````!-<V=E5$585`````$```````9A;'1486=415A4`````0``````#F-E
M;&Q497AT27-(5$U,8F]O;`$````(8V5L;%1E>'1415A4`````0``````"6AO
M<GI!;&EG;F5N=6T````/15-L:6-E2&]R>D%L:6=N````!V1E9F%U;'0````)
M=F5R=$%L:6=N96YU;0````]%4VQI8V5697)T06QI9VX````'9&5F875L=```
M``MB9T-O;&]R5'EP965N=6T````115-L:6-E0D=#;VQO<E1Y<&4`````3F]N
M90````ET;W!/=71S971L;VYG``````````IL969T3W5T<V5T;&]N9P``````
M```,8F]T=&]M3W5T<V5T;&]N9P`````````+<FEG:'1/=71S971L;VYG````
M```X0DE-!!$```````$!`#A"24T$%```````!`````(X0DE-!`P`````"20`
M```!````@````"0```&````V````"0@`&``!_]C_X``02D9)1@`!`@$`2`!(
M``#_[0`,061O8F5?0TT``O_N``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)
M"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,
M#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`"0`@`,!(@`"
M$0$#$0'_W0`$``C_Q`$_```!!0$!`0$!`0`````````#``$"!`4&!P@)"@L!
M``$%`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS
M`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S
M-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U
M5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1
M`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,'
M)C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6
MIK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`/54R=9/4@,;(9DT-V/!
M!?M$;MSMKVOCZ6Y0<SG]C'[ACQ1!]>NL8_O)B+-.LJ'4>L4X5C,9E5N7FVMW
M58E#=SRV0SU++';*,:G<?Y[)MJK_`+:R^HY>!D7W?8G%[Z+33E6-W;#:&[G4
MM?\`S=EE'^']/^9?^BL_2*\_]5Z0U]$LLO;7N=))W/V[G#=^<JYY\QS9\<L8
M`Y>/N2D)WQ1,>*'!'@^;_"3PV`0=S6WVH7XO5,BI^5UG.^P8U;38_%PW[&L8
MV7N.5U%X;D6;6?2=C_8:_P#C/IHOU8;FCI0LRWVO%UMEN*W(UN9C/<78E>0]
MVZQUOH[7N]7]+7O]*S^;4Z^E8F1CU-M9-0?OLK@`6.K=^A]?_2LK=^DV/_PB
ML]3ZCC],P+L_)W&G';N?L&YT2&^UOS5S%,SQQD1PF0XN&^*K\?2QF(B2?W>K
M:27-._Q@_5YK\>3?Z61$Y'I$55N(!=5;:?\`"U;V^OZ/K>C_`(1:/6,FZNRF
MAEAI99J^T>$@<_R)W.3.9SQP8CED"0*%#J9'ABF!C,U$@TZB2SL:C/HR6[;C
MD8KQ+G/=)_L?2_\`(*=GV;]K5;G6"_9[6C^;B'_2_E?23!S),`98SC)R1Q<.
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MSOH_]J;/4_06_HOTEGK5UF^L-F><)N)TXN9DYEK,=U]8EU%5A_3YD?\`!5-?
MZ+O^Y'I(S?V1T#IE=9?5@X&*T,87N#6C^T_Z=ECO^N6V)F3'#)`PF.*,A1".
M(WH:KJYG4:<FBFFJX5!K2\L-0(DGW6.>V&MW.<=RMU8N;E48S;'5-QV-:YK1
MN+CI['/^C[O[2HYN7E=7%;\/'NHQ&R6Y-E1]6P'_`+BXE@_1-T_I&>QG_!8F
M4MCIC6,Q6UM98Q[6M%AM#MQ,?Z2W^<67#DXGG<T<DY&,XPX8\9X\G`(_SDO^
MXXN-DX_2*&W7_O6U76VMC6-X:("Q?KK_`.);J/\`Q8_ZIBW%C_6^B_(^K6?3
MCUONM?6`RNMI<YQW-^BQON<M>(`H#0#1BR:PE_=+Q772/_&SZ1Q/K"/\W*E=
MYD787HX^+F-)-C6D.(@-,;=WJ:;5SO0/J1TC*Z7T_+ZEBVUY;&[K\=Y>QKGA
MWTLC&=^?[&;_`/3?X;U%UN3B493`RYNX#5IX(^#@HN:C.>*4<?`9'IE'%CD/
MTHR6<O$@\4M+C$:?U0Y=8LZ=U&O&JL-E-I$UGMNT_P`[\Y&N_P"7J/\`BS^2
MU6<7IF)BO]2MI+^SG&2)_=178E+LEN40?58-K3)B/=^;_;5''R688XQ/#$#F
M,>>.+BE..'%CEQ2A&<FP9"_I5O`_6RX]!^LN=F-!V=7Z=96UPTVVPVG=_P!;
M]&E__75<R.G_`+._Q8.H(BQ]-=UGCNMMKNVG^HU_IKI>M_5SI7712.HUN?\`
M9RXU[7N9]/;O:=A&YKMC59ZET[%ZG@VX&4TG'N`#VM):8:0]L.9[OI-6I>S5
M.$WDU'J!$/\`#^9X+ZQ3_P"-KTB/&G_SW<KOUL=6>J?5+TR"SU6%NV(VFS"V
MQ'YJZBSZO]+MZ,WHEE9?A,:UC&EQW#8=U;VVSOWL=^<J&/\`47ZO8YQGLJL-
MN)8VZNYUCB\N:6NK:]T_S5>SV4?S/^>E:#AEK5:B'_C;2ZGU!]WUI/3>A8.*
M>L55;LGJF4T'TF%K?;7LBZUVRZK\_P#POI_Z7TZGU!;8WK_U@;;:,BP6`67@
M!HL<+<G?:VMI<UGJ.]VQ;O5/J=T/JF>.H9-=@O(`L-5CJQ8`-GZ7TRUW\W^C
M]FS]&K'2?JYTGHU^1?T^HTG)@/9N)8`TN<QM=9]M;6[_`,U*]$^W,Y!(U0D3
M]"/W7__1[#ZT_8_MF)'[2_:.RST_V5_.>C+/5^T^I^A]#U?2V>I_A/YM"Z-_
MS2^WU>IZO[:@>G^U_5^U=X^S?;_9_P"P"^?TD>C#_E#\OU_E\S]5)+Y5209G
MZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22G_]DX
M0DE-!"$``````%4````!`0````\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`
M:`!O`'`````3`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P`"``-P`N
M`#`````!`#A"24T$!@``````!P`!`````0$`_^$22&AT='`Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2?ON[\G(&ED/2=7-4TP
M37!#96AI2'IR95-Z3E1C>FMC.60G/SX*/#]A9&]B92UX87`M9FEL=&5R<R!E
M<V,](D-2(C\^"CQX.GAA<&UE=&$@>&UL;G,Z>#TG861O8F4Z;G,Z;65T82\G
M('@Z>&%P=&L])UA-4"!T;V]L:VET(#(N."XR+3,S+"!F<F%M97=O<FL@,2XU
M)SX*/')D9CI21$8@>&UL;G,Z<F1F/2=H='1P.B\O=W=W+G<S+F]R9R\Q.3DY
M+S`R+S(R+7)D9BUS>6YT87@M;G,C)R!X;6QN<SII6#TG:'1T<#HO+VYS+F%D
M;V)E+F-O;2]I6"\Q+C`O)SX*"B`\<F1F.D1E<V-R:7!T:6]N(&%B;W5T/2=U
M=6ED.C9E,&(S86(W+3,T864M,3%D82UA.6)F+65E,#@U8S1B-V%F8R<*("!X
M;6QN<SIX87!-33TG:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+VUM+R<^
M"B`@/'AA<$U-.D1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S:&]P.C9E
M,&(S86(U+3,T864M,3%D82UA.6)F+65E,#@U8S1B-V%F8SPO>&%P34TZ1&]C
M=6UE;G1)1#X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*/"]R9&8Z4D1&/@H\+W@Z
M>&%P;65T83X*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"CP_>'!A8VME="!E;F0])W<G/S[_[@`.061O8F4`9(`````!
M_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,#!$,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.%!0.#@X.
M%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_
MP``1"``]`-@#`2(``A$!`Q$!_]T`!``._\0!/P```04!`0$!`0$`````````
M`P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)"@L0``$$
M`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T
M<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2D
MA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$``@(!`@0$
M`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#
M4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34
MY/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1`Q$`/P#U
M5)),3`)\$E+I*G7U3%>X-.ZLNT&]I:#\U8NOJHK]2UVU@TGXJ*',89QE..2)
MC'YC?R?WOW4T>R1)4_VM@?Z7\#_<A974R^HU]-?4_+>8K%VYK)/[VQKG)HYO
MEB0!FQDG0>N*B"!='[&WE9>+ATNR,JUM-+/I/>0!^*Q&]>ZIU4EO0<2,?C]H
M9DLJ/\JBD?IKDU?U?I:]O4/K)D_M#*:996X1CUG]VC&_._KO6SCYM%Q+*VN8
M&-F7-VM@*0YL49C&9Q]P[0OU?XK'626I]$?^=]OZ+S/6[OK1T2BC/?U)F8Y]
MS*G8GHM8UV\_1K<#ZBZX20"=#X+GZ:7]?ZM7U*P1TKI[C]A:?\-;]%^7_P`3
M7]''_P"W%T*D*,8UD03PGY;/%_A>I2222#(I))#=D8[3#K6-/@7`(2E&.LB(
M^9I21),US7"6D$'N-5&VUE3#98=K&\E(R`!D2!$"[Z5W4S20J,FC(!-+]X;H
M45",XSB)1(E$[2B>**E))(>1?5C469%SME532^QQ[-:-SBG*2)+/Z9U[I/57
MO9T_(%[J@'/`#A`/'TVM6@D@$$6""/!22A9;74PV6O;6P<N<0`/[3DU.1CW@
MFBUEH;H2QP='QVI)OHD22224I))))3__T/54DDDE.3U>L.+M)]L@^\Q']7]$
MK'3;Q9T\.N(BN0YSN(;^<Z?Y*;J51)#APX%O#S^%1VK&=TQ_5::^FW9#L;'9
M87Y5#?:ZYA`V5;OS6[Q^D61#]7\3/%48YHRC_>E_.0XOZZ^1/MV!Q$=&74+*
M;<DVXY:ZFQK7L<W@@CZ06MT9C/L37;1NW.UC7E974::J,GT*6AE53&,K8.`T
M-AK0M;I#FMZ>'.(#0723\54Y`1_TKS.@H>[]/UD5TK]N-[Z-+J#C?U+TW:LJ
M&C8<1Q)_F_<KXQ6Y6$RFPGTG_P`ZT%TN$_S9-GZ38[\]9@)OS+LAH.QQ(:8>
M0>W^"A;M+-E36=P`#S_W[W*Y\,N>?F,VA$Y2J7Z7#Q?J_P#!X8+<@'"`R:UK
M&AC`&M:(:T:``=@AY.5CXE#\C)L;536)?8XP`.-458?UU_\`$OG_`-1O_5L6
ML-V*9X8RD/T03]C<9U_HK\5^8W,J.-6[8^W<-H=&[9_63].Z[TCJA<W`RF7O
M9JY@,.`\=CMKEP/U%^K^!UIF4>H;[*L9S?3I#BUFYX.ZQVW\_P!BI8M7[$^N
M]>-C..RG*%0)Y-=D-V._L/3N$:CLU1S.3AQS,1P3/#OZGTKK.393CM96=KK#
M!(Y@<JAA=).50;C9MDD-$3Q^\M7J&&,NC8#M>TRP^?@L:N[.Z;86D%H/+':M
M/P7/?$8"/.C+S4)9.4,>&/#?#CEX\+HP^6HFI)NGLSL7+](,<ZO=MLCZ/]<+
M7RV4OQWMO=LK(]SIB-4'!ZE3E^WZ%HU+#W_JI^J?T"[X#\H5SEH8L7(Y3BR?
M>,7#.<1/Y8CA_FO^^6DDR%BBMTZK#J:\8MGJ`D;C,P5#'Z]T;*R1B8^959D$
MD"IKO=+?IZ?R4'H'\U=_6'Y%P756?L+Z]B]OMJ-[+Q_4M_G?^JL5GX;(9.5Q
MR$1CL&H0^6/JDP<SD.(@[@R$9$^+Z3G=2P.G5MLSKV8['G:USS`)YA!NR.F=
M2Z1?9Z[78%M;VV7L.@;!;8X/_DKB?\9V8;,[#P&&?38;2T?O6'8S_HL73W8(
MZ?\`4RW#`@TX3P[^L6.=9_TRKE:`]UGNF4\D:'#C'_.[(/JGTWZM85^0[HN8
M<JQ[&BT%X?#03M/M:Q;F=U'!Z?3Z^;<RBJ8#GF)/@W]Y<'_BM_IF?_Q5?_5.
M0/\`&7DVV=:HQI/ITTAS6]MSW.W._P"BU*KE3''/P<N,@B!K0B/EW>A^M75^
MF=4^JF<[!R&9`:&;FM/N'O9])CO<J7^*T`86?_QK/^I5?ZP_4[I73?JT<W'W
MMRZ6,]2S<2+-Q:UX>SZ.WW*S_BN_H6?_`,:S_J4=.$UW6@S/-8^,`'@/R[?I
M/79W4L#I]8LS<BO'8>"]P$_U1])RIXGUI^K^9:*:,ZIUCC#6DEI)_D^IM7-]
M7^I76>L=>?F9E]8PG/AH:XE[*1PUC2W9O6#]<NC=#Z7;CMZ5?O>[<+Z=XL+2
MV-C]/H;D``>J_)GRPXI<`$(FO4?5+^Z^KI+)^JN5=E_5[!OO=OL=4`YQY.TE
MDG_-20K6FQQC@X^G#Q/_T?55%[V5L=98X-8P%SG'0`#DE27*]=NNZ]U<?5O$
M>68E(%O5+F\[>68S3_+2"V<^$=R=(CO))@9O4?K%U/[7CO=C="Q2YC=(.4[Z
M+IG_``#5J6]$H>[<RQ[#VD[OR^Y7L?'IQJ&8]#!754T-8QN@`"(H<_+8,]>[
MC$ZV_>_QHIQ\4!\UDZR>7S:#CY+JB\V$`>X\ZA6\'I8RL<6.M<UI)&P<:%4^
MMY3&]4=CU`WY3@"W'KU=$?2?^;57_P`)8M3HN/<<9K\BQKH)VU5_0:9[O/NN
M=_+^@L+E/A\9<[F&3'^HO(,8D3'CX9_HZ\>2,66630")N6EU^CYMO%Z=1BG<
MTN<X<%QX^#?HJTDDN@Q8L>*(ACB(1'2*PDG=2Q/KK_XE\_\`J-_ZMBVUB?77
M_P`2^?\`U&_]6Q2#<,>7^;G_`'9?DX'^*W^8ZC_7J_(]8?4??_C`.W7]>K&G
MD62I?4_HF;U+'S+^G9K\',H<QK'-)#'-<'$MLV^[LM[ZM_4/+PNJ,ZEU2YEC
MZ7%]=;"7%SS_`(2RQX:GF@26C",\F+#`1T$N+CZ5;U>?GC##9K+]\P08&B?'
MNHZAC2]H,Z/8=8*)DXU>34:K.#J".0?%9+NB9;''TK&EI[R6F/.%D\S/G<><
MRCC^\\M.->T.$2A+_NG4CPD;T>[5(%'4-M!D,L`8?FMOJG]`N^`_*$#!Z.W'
ML%MSM[V_1`X!\5;S*'9&,^EI`+QH3QRH>2Y/-CY7FA*/!+.)G'A!O@],N$)E
M(&4?#JT>@?S5W]8?D7+_`.-#`]N'U%HX+J+#\?TE7_HQ=ATW!LPV/:]P=O((
MCR0/K)T<]9Z1=@M<UECMKJGNX#FG=V5[X9CGBY7%#(.&40>*/^%)@YJ'N0F!
MK>WF'SKI3K?K'];,1]PD#TS8#K[:&-W?Y[F?]->D_6#_`)"ZA_X6M_ZARQ/J
MC]3LCH69=EY5M=SWUBNOTP=).Y_TOZK5T/4\5^9T[*Q*R&OOJ?6USN`7-+9*
MN2(L5T8<&*<<4^(>N=DO"_XK?Z9G_P#%5_\`5.5+_&."WZQM<>/0K/W%ZZCZ
MG_5/,Z!?DVY-U=HO8UK17.A:2==WQ4_KA]47=>]+(QK&U9=(+/?.U["=VUQ;
M]':Y&QQ6Q>QD/*B%>L'BX?JS^N;FN^J&0YIEKF5$'Q!<Q97^*[^A9_\`QK/^
MI4*?J'UF_I[L?J742\5L+<3&#G&ICOS7V$Q]#]S8MKZG_5S*Z!CY-63:RTWO
M:YIKG0`;==R&E$6OC')+/#(8&($:>6ZAUGJWUJZ[^Q\&\XN$7N8T`D2UD^I=
M;M]S_H^VI5_KC]6NG=!Q<)F*YS[[G/\`6L>=7`!NWV#VL;JM+._Q>]5JZF[+
MZ/E,K87FRLN+F/K+C.W<QKMRGG?XN^IY=;+KNH_:,]Q/K67;BP-_-95])WTD
M;&FNC#+%EE'()8S+(3I,G01_J/1?4O\`\3&!_4/_`%;TE:^K_3KNE]'QL"YS
M7V4-+7.9,&7.=IN_K))O7ZMSA/L\->K@JO'A?__2]-SLVC!Q795YVU,+0YW8
M;G!DG_.5+HG26]-=G7FUMQSLAV1ZO?8[Z#''_@_<C];_`&=^R<K]I_T+TSZW
M,Q_)C\_=]!>=4#ZI;1N=U@XG8$`5Q\:W%$;,4^(3C41+]VY<)XOTGN^I_6SH
M?33LLR!=?PW'H_2/)_=VL^C_`&E2KL^M'73.T]#Z<[OH[*>/*?;CHGU;_P"9
MT#]B>AZL:S_/?/UOTRZ%+3HGAG+YY4/W8?MFXE7U=&-4:,1S:JW&;#JZRP_O
MY%SO?:Y6\/"S<7:P7,-0,ENW7S@K025'[KR_WCCXY?>*NO=E[G!_<XOYMEC+
MT`1`X.E#TJ2225U"EG]>Z:_JO2<G`K>*WWM#0]PD"'-=V_JK0221(`Q(EM6O
MD\]]4?JS?]7Z\EEU[+_M#F.!8"(VAP_._K+H4DD3=ZK<8@(`0UCTH\2DDDD%
AZDDDDE*22224I))))2DDDDE*22224I))))2DDDDE/__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>logo_pr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo_pr.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X0=T17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````4````<@$R``(````4````AH=I``0````!````G````,@```!(````
M`0```$@````!061O8F4@4&AO=&]S:&]P(#<N,``R,#`U.C$P.C`T(#`T.C$U
M.C$X``````.@`0`#`````?__``"@`@`$`````0```"V@`P`$`````0```#4`
M````````!@$#``,````!``8```$:``4````!```!%@$;``4````!```!'@$H
M``,````!``(```(!``0````!```!)@("``0````!```&1@````````!(````
M`0```$@````!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``O_N
M``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43
M$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-
M$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#/_``!$(`#4`+0,!(@`"$0$#$0'_W0`$``/_Q`$_```!
M!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$`
M`@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@`,`P$``A$#$0`_`&^K?U<P.HX`RLK<7;GM):XC@C8M8?4GHD#<+9)TAY4?
MJ8!^Q6RR6MML<.-73^:MDN#B'[3NGV\2W0\ZJ4VV\DY\1J1W<=OU)Z,3_A'"
M=?>1HHW?4?IC6N?47N@2&%Q[>8*VG@>FVTL]\B'")$G^LW^JBFX!A=:P[1,N
MT.@'TM"AKW6\<]Q(GZO.-^J'2'P#ZE3AH07$R?O65_S>Q_\`G$>F:^CZ0?&X
MS,<[I7=644W`BQ@=/)("YC[/7_SQ-$?H_LH';]U(;VNQY)'BU/RDO__0TOJ<
MY_[%;6!(+[23'!ENU;9%A+"P@B8)VDG\JP_J?6UW1F.+`X^I9!@2-9G<5O%C
M)]1M?N'8`;M>5*=VSDKC/F5$VM,F(T`@<:^[=[DG%S6N<2!H2TM&GE^^F=56
M[W^EJ"#O``,S^<F?6`QVVL-,$!S0(B-W&OYW\A+1;I_(,YMW?2#7$=QH3]ZY
M_<[_`)[%T>[[,-/[*Z"`7[G,U(T<8(T/Q7,^S_G>3Z8V_90=DC;]'=S]#:D%
M^/\`2_NE_]&ETEOUJ_8]V5TO,JJQ<;U[/LWL-SA3Z;\FQ@MQ;6[6^O5_VI6E
MDXG^,"JS&K=U3'<_(NKI`8&^UUK++JC<YW3V?H]M3OYOUEF=-POK)F?5V\8!
MJ9TVM^0ZUI<6/<YK:38Q[C7Z'Z3V>CONK_PBVK7_`%O==TN^^O"<,RW'?AG<
M^&6^E;Z5EGZ/V.^S^I7;Z?J*0R/A]C:F!Q$\0NY->S%^OS,MN,>J8^\L=8ZP
MM:UC&M?75[S;T^MWN=;^;7L_TCU7:?KP_IF3U$]1I9C4.M:6GT2ZPU?SOH;,
M2RE^[_!;K6>M_@T3$OZEU3K%K^G=+Z;3F].(=>Y];/?-K/?6ZNIWZ5MM?J5V
MOV6U_P#@:;U.O.Z-U;-^QX`KM&87P&#(>T`4]2R,<NKV65,]3])ZMU;W[/YO
MZ"5GP^Q%4=:Z.-_SJ^LH$#J#X_XJC_T@J_[9ZMZYS?M)^U[0SUME<[?W=GI>
ME_X$K=GU2ZPPX1(Q[&YUK*:;:WN?6UU@!9ZE[:?2[[?T3[4__-#K/VO]F[*?
MM!J]<#U/9M!V%N[T]V_7]S^VG<0\/L9X^R+KJ/ZWR]7_TJ/0_P#G1]CM_9I_
M4(R/4]04;-L4?;-_J^_9M]'^<_ZTK=O_`#J];IFXXWVG]'^SH&/ZVW:_[-_W
M8]#T]W\_^C_TGZ5>6I*4]=G0._\`D^OG_A/I@_;OVO*],]-_FV_;X&#Z$>K^
MC^U?X'U_M/T-_P"E]16!_P`]OV+9Z!K_`&/Z&1O](8WH>G^D^T_1/_'?R/\`
MH+RM)(_X/39!Z?S6X?6+O^?,,@TS]HKW>B,3=Z^GV3[1Z?NW_P`WZ7J_]>6?
M'4/MHUZ5O^SZ:8?V;;/Q^R_:/4_Z]_Z#KS=)`==DQZ_S>QVV^K__V?_M#"A0
M:&]T;W-H;W`@,RXP`#A"24T$)0``````$``````````````````````X0DE-
M`^T``````!``2`````$``0!(`````0`!.$))300F```````.````````````
M`#^````X0DE-!`T```````0```!X.$))3009```````$````'CA"24T#\P``
M````"0```````````0`X0DE-!`H```````$``#A"24TG$```````"@`!````
M``````$X0DE-`_4``````$@`+V9F``$`;&9F``8```````$`+V9F``$`H9F:
M``8```````$`,@````$`6@````8```````$`-0````$`+0````8```````$X
M0DE-`_@``````'```/____________________________\#Z`````#_____
M________________________`^@`````____________________________
M_P/H`````/____________________________\#Z```.$))300````````"
M``$X0DE-!`(```````0`````.$))300(```````0`````0```D````)`````
M`#A"24T$'@``````!``````X0DE-!!H``````T,````&```````````````U
M````+0````<`;`!O`&<`;P!?`'``<@````$`````````````````````````
M`0``````````````+0```#4``````````````````````0``````````````
M```````````0`````0```````&YU;&P````"````!F)O=6YD<T]B:F,````!
M````````4F-T,0````0`````5&]P(&QO;F<``````````$QE9G1L;VYG````
M``````!"=&]M;&]N9P```#4`````4F=H=&QO;F<````M````!G-L:6-E<U9L
M3',````!3V)J8P````$```````5S;&EC90```!(````'<VQI8V5)1&QO;F<`
M````````!V=R;W5P241L;VYG``````````9O<FEG:6YE;G5M````#$53;&EC
M94]R:6=I;@````UA=71O1V5N97)A=&5D`````%1Y<&5E;G5M````"D53;&EC
M951Y<&4`````26UG(`````9B;W5N9'-/8FIC`````0```````%)C=#$````$
M`````%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<`
M```U`````%)G:'1L;VYG````+0````-U<FQ415A4`````0```````&YU;&Q4
M15A4`````0```````$US9V5415A4`````0``````!F%L=%1A9U1%6%0````!
M```````.8V5L;%1E>'1)<TA434QB;V]L`0````AC96QL5&5X=%1%6%0````!
M```````):&]R>D%L:6=N96YU;0````]%4VQI8V5(;W)Z06QI9VX````'9&5F
M875L=`````EV97)T06QI9VYE;G5M````#T53;&EC959E<G1!;&EG;@````=D
M969A=6QT````"V)G0V]L;W)4>7!E96YU;0```!%%4VQI8V5"1T-O;&]R5'EP
M90````!.;VYE````"71O<$]U='-E=&QO;F<`````````"FQE9G1/=71S971L
M;VYG``````````QB;W1T;VU/=71S971L;VYG``````````MR:6=H=$]U='-E
M=&QO;F<``````#A"24T$$0```````0$`.$))3004```````$`````CA"24T$
M#``````&8@````$````M````-0```(@``!PH```&1@`8``'_V/_@`!!*1DE&
M``$"`0!(`$@``/_M``Q!9&]B95]#30`"_^X`#D%D;V)E`&2``````?_;`(0`
M#`@("`D(#`D)#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,
M#`P1$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`
M-0`M`P$B``(1`0,1`?_=``0``__$`3\```$%`0$!`0$!``````````,``0($
M!08'"`D*"P$``04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"
M!0<&"`4###,!``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,'
M)9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34
MY/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'
M!P8%-0$``A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T
M\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%
MU>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`;ZM_5S`Z
MC@#*RMQ=N>TEKB."-BUA]2>B0-PMDG2'E1^I@'[%;+):VVQPXU=/YJV2X.(?
MM.Z?;Q+=#SJI3;;R3GQ&I'=QV_4GHQ/^$<)U]Y&BC=]1^F-:Y]1>Z!(87'MY
M@K:>!Z;;2SWR(<(D2?ZS?ZJ*;@&%UK#M$R[0Z`?2T*&O=;QSW$B?J\XWZH=(
M?`/J5.&A!<3)^]97_-['_P"<1Z9KZ/I!\;C,QSNE=U913<"+&!T\D@+F/L]?
M_/$T1^C^R@=OW4AO:['DD>+4_*2__]#2^ISG_L5M8$@OM),<&6[5MD6$L+""
M)@G:2?RK#^I];7=&8XL#CZED&!(UF=Q6\6,GU&U^X=@!NUY4IW;.2N,^943:
MTR8C0"!QK[MWN2<7-:YQ(&A+2T:>7[Z9U5;O?Z6H(.\``S/YR9]8#';:PTP0
M'-`B(W<:_G?R$M%NG\@SFW=](-<1W&A/WKG]SO\`GL71[OLPT_LKH(!?N<S4
MC1Q@C0_%<S[/^=Y/IC;]E!V2-OT=W/T-J07X_P!+^Z7_T:726_6K]CW972\R
MJK%QO7L^S>PW.%/IOR;&"W%M;M;Z]7_:E:63B?XP*K,:MW5,=S\BZND!@;[7
M6LLNJ-SG=/9^CVU._F_669TW"^LF9]7;Q@&IG3:WY#K6EQ8]SFMI-C'N-?H?
MI/9Z.^ZO_"+:M?\`6]UW2[[Z\)PS+<=^&=SX9;Z5OI66?H_8[[/ZE=OI^HI#
M(^'V-J8'$3Q"[DU[,7Z_,RVXQZIC[RQUCK"UK6,:U]=7O-O3ZW>YUOYM>S_2
M/5=I^O#^F9/43U&EF-0ZUI:?1+K#5_.^ALQ+*7[O\%NM9ZW^#1,2_J75.L6O
MZ=TOIM.;TXAU[GUL]\VL]];JZG?I6VU^I7:_9;7_`.!IO4Z\[HW5LW['@"NT
M9A?`8,A[0!3U+(QRZO994SU/TGJW5O?L_F_H)6?#[$51UKHXW_.KZR@0.H/C
M_BJ/_2"K_MGJWKG-^TG[7M#/6V5SM_=V>EZ7_@2MV?5+K##A$C'L;G6LIIMK
M>Y];76`%GJ7MI]+OM_1/M3_\T.L_:_V;LI^T&KUP/4]FT'86[O3W;]?W/[:=
MQ#P^QGC[(NNH_K?+U?_2H]#_`.='V.W]FG]0C(]3U!1LVQ1]LW^K[]FWT?YS
M_K2MV_\`.KUNF;CC?:?T?[.@8_K;=K_LW_=CT/3W?S_Z/_2?I5Y:DI3UV=`[
M_P"3Z^?^$^F#]N_:\KTSTW^;;]O@8/H1ZOZ/[5_@?7^T_0W_`*7U%8'_`#V_
M8MGH&O\`8_H9&_TAC>AZ?Z3[3]$_\=_(_P"@O*TDC_@]-D'I_-;A]8N_Y\PR
M#3/VBO=Z(Q-WKZ?9/M'I^[?_`#?I>K_UY9\=0^VC7I6_[/IIA_9ML_'[+]H]
M3_KW_H.O-TD!UV3'K_-[';;ZO__9.$))300A``````!5`````0$````/`$$`
M9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P````$P!!`&0`;P!B`&4`(`!0
M`&@`;P!T`&\`<P!H`&\`<``@`#<`+@`P`````0`X0DE-!`8```````<``0``
M``$!`/_A$DAH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O`#P_>'!A8VME
M="!B96=I;CTG[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED)S\^
M"CP_861O8F4M>&%P+69I;'1E<G,@97-C/2)#4B(_/@H\>#IX87!M971A('AM
M;&YS.G@])V%D;V)E.FYS.FUE=&$O)R!X.GAA<'1K/2=835`@=&]O;&MI="`R
M+C@N,BTS,RP@9G)A;65W;W)K(#$N-2<^"CQR9&8Z4D1&('AM;&YS.G)D9CTG
M:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R<@
M>&UL;G,Z:5@])VAT='`Z+R]N<RYA9&]B92YC;VTO:5@O,2XP+R<^"@H@/')D
M9CI$97-C<FEP=&EO;B!A8F]U=#TG=75I9#IF9C(Y.6-C,2TS-&%E+3$Q9&$M
M83EB9BUE93`X-6,T8C=A9F,G"B`@>&UL;G,Z>&%P34T])VAT='`Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]M;2\G/@H@(#QX87!-33I$;V-U;65N=$E$/F%D
M;V)E.F1O8VED.G!H;W1O<VAO<#HV93!B,V%B92TS-&%E+3$Q9&$M83EB9BUE
M93`X-6,T8C=A9F,\+WAA<$U-.D1O8W5M96YT240^"B`\+W)D9CI$97-C<FEP
M=&EO;CX*"CPO<F1F.E)$1CX*/"]X.GAA<&UE=&$^"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H\/WAP86-K970@96YD
M/2=W)S\^_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`-0`M`P$B``(1`0,1`?_=``0`
M`__$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`;ZM_5S`ZC@#*RMQ=N>TEKB."-JUA]2>B
M0-PMDG2'E1^I@'[%;+):VVQPXU=/YJV2X.A^T[I]O$MT/.JE-MN<Y\1J1W<=
MOU)Z,3_A'"=?>1HHW?4?IC6N?47F!(87'MY@K:>!Z;;2SWR(<(D2?ZS?ZJ(;
M@&%UK#M$R[0Z`?2T*&O=;QY-Q(GZO.M^J'2'P#ZE;AH07$R?O65_S>Q_^<1Z
M9KZ/I!\;C,QSNE=U913<"+&!T\D@+F/L]?\`SQ-$?H_LL=N-J0/5=#)(\6I^
M4E__T-+ZG.?^Q6U@3+[23'!ENU;1#R6%A!$P2&DG\JQ/J?6'=&8XL#B++(,"
M1K,[BMXL9/J-K]P[`#<)Y4I;.2N,^9476M,F(T`('&ONW>Y)Q<UKB2!H=I:-
M/+]],^JMWO\`2$@@[P`#,_G)GU@,=MK#3!`<T"(C=QK^=_(26Z?R#.;=WT@U
MQ'<:$_>N?W._Y[%T>[[,-/[*Z"`7[G,U(T<8(T/Q7,^S_G>3Z8V_99V2-OT=
MW/T4@OQ_I?W2_P#_T:726_6K]CW972\RJK%QO7L^S>PW.%/IOR;*Q;BVLVM]
M>K_M2M+)Q/\`&!59C5NZICN?D75T@,#?:ZUEEU1N<[I[/T>VIW\WZRS.FX7U
MDS/J[>,`U,Z;4_(=:TN+'N<UM)L8]QK]#])[/1WW5_X1;5K_`*WNNZ7??7A.
M&;;COPSN?#+?2M]*RS]'['?9_4KM]/U%(9'P^QM3`XB>(7<FO9C?7YF6W&/5
M,?>6.L=86M:QC6OKJ]YMZ?6[W.M_-KV?Z1ZKM/UX?TS)ZB>HTLQJ'6M+3Z)=
M8:OYWT-F)92_=_@MUK/6_P`&B8E_4NI]8M?T[I?3:<WIQ#KW/K9[YM9[ZW5U
M._2MMK]6NU^RVO\`\#3"SKSNC=6S?L>`*[1F%\!@R'M`%/4LC'+J]EE3?4_2
M>K=6]^S^;^@E9\/L15'6NCC_`/.KZR`0.H/C_BJ/_2"K?MGJWKG-^TG[7MV>
MMLKG;^[L]+TO_`E;L^J76&'",8]C<ZUE--M;W/K:ZP`L]2]M/I=]OZ)]J?\`
MYH=9^U_LW91]H-7K@;_9M!V%N[T]V_\`L)W$/#[&<>SK74?UOEZO_]*CT/\`
MYT?8[?V:?U",CU/4%&S;%'VS?ZOOV[?1_G/^M*Y;_P`Z?6Z9N.-]I_1_LZ!C
M^MMVO^S?]V/0]/=_/_H_])^E7EB2E/7;]KH'?_)]?/\`PGTT?MW[7E>F>F_S
M;?M\#!]"/5_1_:O\#Z_VGZ._]+O1Q_SV_8C_`$#7^Q_0R-_I#&]#T_TGVF=A
M_P"._D?]!>5I)'_!Z;(/3^:W#ZQ=_P`^89!IG[17N]$8F[U]/LGVCT_=O_F_
M3]7_`*ZL^.H?;1KTK?\`9]-,/[-MGX_9?M/J?]>_]!UYND@.NR8]?YOKM_W3
"_]D_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
